Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter

被引：6
|
作者：
Businello, Gianluca [1 ]
Angerilli, Valentina [1 ]
Lonardi, Sara [2 ]
Bergamo, Francesca [2 ]
Valmasoni, Michele [3 ]
Farinati, Fabio [3 ]
Savarino, Edoardo [3 ]
Spolverato, Gaya [3 ]
Fassan, Matteo [1 ,2 ]
机构：
[1] Univ Padua, Dept Med DIMED, Padua, Italy
[2] Ist Ricovero & Cura Carattere Sci IRCCS, Veneto Inst Oncol, Padua, Italy
[3] Univ Padua, Dept Surg Oncol & Gastroenterol DISCOG, Padua, Italy
来源：
UPDATES IN SURGERY | 2023年 / 75卷 / 02期
关键词：
Gastric adenocarcinoma; Gastroesophageal junction adenocarcinoma; Biomarkers; Immunohistochemistry; ADVANCED GASTRIC-CANCER; TYROSINE KINASE INHIBITOR; FGFR2 GENE AMPLIFICATION; DOUBLE-BLIND; OPEN-LABEL; 1ST-LINE THERAPY; HER2; STATUS; PHASE-II; MICROSATELLITE INSTABILITY; GASTROESOPHAGEAL CANCER;
D O I：
10.1007/s13304-022-01330-5
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
The comprehensive molecular characterization of gastric and gastroesophageal junction adenocarcinomas has led to the improvement of targeted and more effective treatments. As a result, several biomarkers have been introduced into clinical practice and the implementation of innovative diagnostic tools is under study. Such assessments are mainly based on the evaluation of limited biopsy material in clinical practice. In this setting, the pathologist represents a key player in the selection of patients facilitating precision medicine approaches.
引用
收藏
页码：291 / 303
页数：13
相关论文
共 50 条
  • [1] Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
    Gianluca Businello
    Valentina Angerilli
    Sara Lonardi
    Francesca Bergamo
    Michele Valmasoni
    Fabio Farinati
    Edoardo Savarino
    Gaya Spolverato
    Matteo Fassan
    Updates in Surgery, 2023, 75 : 291 - 303
  • [2] Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
    Shitara, Kohei
    Shah, Manish A.
    Lordick, Florian
    Van Cutsem, Eric
    Ilson, David H.
    Klempner, Samuel J.
    Kang, Yoon-Koo
    Lonardi, Sara
    Hung, Yi-Ping
    Yamaguchi, Kensei
    Enzinger, Peter
    Nakajima, Tomoko
    Matsangou, Maria
    Cao, Ying
    Li, Ran
    Moran, Diarmuid
    Pophale, Rupesh
    Oh, Mok
    Ranganath, Radhika
    Ajani, Jaffer A.
    Xu, Rui-Hua
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (12): : 1160 - +
  • [3] Biomarkers of neoadjuvant combinational therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma
    Wang, Y.
    Yang, J.
    Zhou, X.
    Liu, Q.
    Yang, Y.
    Guan, W.
    Liu, B.
    Wei, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S245 - S245
  • [4] Pathologist reproducibility of combined positive score (CPS) for the evaluation of PD-L1 in gastric or gastroesophageal junction adenocarcinoma tumors
    Guerrero, Lindsay
    Kulangara, Karina
    Truong, Yen
    Schwefel, Sue
    Hanks, Debra
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Comprehensive Molecular Characterization of Adenocarcinoma of the Gastroesophageal Junction Between Esophageal and Gastric Adenocarcinomas
    Suh, Yun-Suhk
    Na, Deukchae
    Lee, Ju-Seog
    Chae, Jeesoo
    Kim, EuiHyun
    Jang, Giyong
    Lee, Jieun
    Min, Jimin
    Ock, Chan-Young
    Kong, Seong-Ho
    George, Joshy
    Zhang, Chengsheng
    Lee, Hyuk-Joon
    Kim, Jong-Il
    Kim, Seong-Jin
    Kim, Woo Ho
    Lee, Charles
    Yang, Han-Kwang
    ANNALS OF SURGERY, 2022, 275 (04) : 706 - 717
  • [6] Biomarkers of response in patients with gastric/gastroesophageal junction adenocarcinoma (GEA) treated with telisotuzumab adizutecan.
    Strickler, John H.
    Raimbourg, Judith
    Ghiringhelli, Francois
    Cohen, Jonathan
    Kitagawa, Chiyoe
    Sharma, Manish R.
    Lee, Ki Hyeong
    Saada-Bouzid, Esma
    O'Neil, Bert
    Rudra-Ganguly, Nandini
    Luo, Xizhi
    Roberts-Rapp, Lisa
    Predoiu, Raluca
    Zhao, Weilong
    Li, Rui
    Hunter, Zoe
    Burns, Michael Charles
    Blaney, Martha Elizabeth
    Kuboki, Yasutoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 490 - 490
  • [7] ANALYSIS OF SURGICAL INCURABILITY IN GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
    Zhao, H.
    Chen, W.
    Lin, Y.
    Qin, J.
    Wang, L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : E7 - E7
  • [8] Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma
    Joshi, Smita S.
    Maron, Steven B.
    Catenacci, Daniel V.
    FUTURE ONCOLOGY, 2018, 14 (05) : 417 - 430
  • [9] NEJM at ESMO - Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
    Rubin, Eric J.
    Yeku, Oladapo O.
    Morrissey, Stephen
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (12):
  • [10] Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction
    Lagarde, S. M.
    ten Kate, F. J. W.
    Richel, D. J.
    Offerhaus, G. J. A.
    van Lanschot, J. J. B.
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 977 - 991
12345